Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)
China flag China · Delayed Price · Currency is CNY
13.20
+0.01 (0.08%)
Nov 17, 2026, 3:04 PM CST

SHE:300497 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
1,9621,1821,1731,5971,6331,388
Other Revenue
3.43.44.8812.3914.2841.15
1,9661,1851,1781,6101,6471,430
Revenue Growth
102.59%0.61%-26.83%-2.28%15.23%-4.25%
Cost of Revenue
1,182995.171,1241,4711,433996.18
Gross Profit
784.17189.8253.88138.32214.38433.36
Selling, General & Admin
173.48151.94152.9193.55179.91163.47
Research & Development
75.0659.574.6697.4577.4578.51
Other Operating Expenses
48.1113.059.6716.5315.2314.58
Operating Expenses
326.61230.92236.36308.44273.38260.29
Operating Income
457.56-41.1-182.48-170.12-59173.07
Interest Expense
-51.48-46.24-40.58-42.03-41.1-24.92
Interest & Investment Income
36.385.516.689.2923.2916.4
Currency Exchange Gain (Loss)
-3.31-3.318.297.918.81-3.81
Other Non Operating Income (Expenses)
-11.433.83-2.48-4.54-3.51-0.21
EBT Excluding Unusual Items
427.71-81.32-210.57-199.5-61.5160.53
Impairment of Goodwill
----1.15-1.07-
Gain (Loss) on Sale of Investments
-12.88-13.82-13.99-15.5-82.93-131.99
Gain (Loss) on Sale of Assets
-0.25-0.38-0.10.080.41-0.06
Asset Writedown
-21.21-6.58-101.63-23.74-12.82-2.01
Other Unusual Items
42.836.8937.736.6415.2128.61
Pretax Income
436.17-65.21-288.56-233.17-142.7155.07
Income Tax Expense
35.58-2.24-8.11-9.9121.4715.53
Earnings From Continuing Operations
400.58-62.97-280.45-223.26-164.1739.54
Minority Interest in Earnings
10.037.948.3522.4622.79.29
Net Income
410.62-55.03-272.1-200.8-141.4748.83
Net Income to Common
410.62-55.03-272.1-200.8-141.4748.83
Net Income Growth
------84.71%
Shares Outstanding (Basic)
561550534543544543
Shares Outstanding (Diluted)
561550534543544543
Shares Change
4.31%3.14%-1.69%-0.26%0.29%17.25%
EPS (Basic)
0.73-0.10-0.51-0.37-0.260.09
EPS (Diluted)
0.73-0.10-0.51-0.37-0.260.09
EPS Growth
------86.96%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
59.09-162.2145.89-306.99-580.26-607.28
Free Cash Flow Per Share
0.10-0.290.09-0.57-1.07-1.12
Dividend Per Share
0.050-----
Dividend Growth
------
Gross Margin
39.89%16.02%4.57%8.59%13.01%30.31%
Operating Margin
23.28%-3.47%-15.49%-10.57%-3.58%12.11%
Profit Margin
20.89%-4.64%-23.10%-12.47%-8.59%3.42%
Free Cash Flow Margin
3.01%-13.69%3.90%-19.07%-35.23%-42.48%
EBITDA
656.8146.08-11.39-10.6664.84271.64
EBITDA Margin
33.41%12.33%-0.97%-0.66%3.94%19.00%
D&A For EBITDA
199.25187.18171.09159.46123.8498.57
EBIT
457.56-41.1-182.48-170.12-59173.07
EBIT Margin
23.28%-3.47%-15.49%-10.57%-3.58%12.11%
Effective Tax Rate
8.16%----28.20%
Revenue as Reported
1,9661,1851,1781,6101,6471,430
Advertising Expenses
-4.244.056.19-4.19